# Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

> **NCT05461573** · PHASE3 · COMPLETED · sponsor: **Insud Pharma** · enrollment: 1542 (actual)

## Conditions studied

- Contraception
- Change in Bone Mineral Density

## Interventions

- **DRUG:** Drospirenone

## Key facts

- **NCT ID:** NCT05461573
- **Lead sponsor:** Insud Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-02
- **Primary completion:** 2024-08-05
- **Final completion:** 2025-05-27
- **Target enrollment:** 1542 (ACTUAL)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461573, "Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05461573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*